HK1212990A1 - 用於治療過早衰老和尤其是早衰的化合物 - Google Patents

用於治療過早衰老和尤其是早衰的化合物

Info

Publication number
HK1212990A1
HK1212990A1 HK16101060.5A HK16101060A HK1212990A1 HK 1212990 A1 HK1212990 A1 HK 1212990A1 HK 16101060 A HK16101060 A HK 16101060A HK 1212990 A1 HK1212990 A1 HK 1212990A1
Authority
HK
Hong Kong
Prior art keywords
compounds useful
premature aging
treating premature
progeria
particular progeria
Prior art date
Application number
HK16101060.5A
Other languages
English (en)
Inventor
．塔澤
．馬于托
．納日曼
．謝雷
．桑托斯
Original Assignee
Abivax
Centre Nat De La Rech Scientifique(Cnrs)
Inst Curie
Univ Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09162630A external-priority patent/EP2261214A1/en
Priority claimed from EP20090305540 external-priority patent/EP2266972A1/en
Application filed by Abivax, Centre Nat De La Rech Scientifique(Cnrs), Inst Curie, Univ Montpellier filed Critical Abivax
Publication of HK1212990A1 publication Critical patent/HK1212990A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK16101060.5A 2009-06-12 2013-01-17 用於治療過早衰老和尤其是早衰的化合物 HK1212990A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18655209P 2009-06-12 2009-06-12
US18654409P 2009-06-12 2009-06-12
EP09162630A EP2261214A1 (en) 2009-06-12 2009-06-12 Compounds useful to treat premature aging and in particular progeria
EP20090305540 EP2266972A1 (en) 2009-06-12 2009-06-12 New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies

Publications (1)

Publication Number Publication Date
HK1212990A1 true HK1212990A1 (zh) 2016-06-24

Family

ID=43309298

Family Applications (8)

Application Number Title Priority Date Filing Date
HK13100514.2A HK1173153A1 (zh) 2009-06-12 2013-01-11 用於治療癌症的化合物
HK13100736.4A HK1173726A1 (zh) 2009-06-12 2013-01-17 用於治療 的化合物
HK16101079.4A HK1213246A1 (zh) 2009-06-12 2013-01-17 用於治療過早衰老和尤其是早衰的化合物
HK16101080.1A HK1213247A1 (zh) 2009-06-12 2013-01-17 用於治療過早衰老和尤其是早衰的化合物
HK16101060.5A HK1212990A1 (zh) 2009-06-12 2013-01-17 用於治療過早衰老和尤其是早衰的化合物
HK13100731.9A HK1173447A1 (zh) 2009-06-12 2013-01-17 用於治療過早衰老和尤其是早衰的化合物
HK16100761.9A HK1212702A1 (zh) 2009-06-12 2013-01-17 用於治療過早衰老和尤其是早衰的化合物
HK15101062.4A HK1200363A1 (zh) 2009-06-12 2015-01-30 用於治療癌症的化合物

Family Applications Before (4)

Application Number Title Priority Date Filing Date
HK13100514.2A HK1173153A1 (zh) 2009-06-12 2013-01-11 用於治療癌症的化合物
HK13100736.4A HK1173726A1 (zh) 2009-06-12 2013-01-17 用於治療 的化合物
HK16101079.4A HK1213246A1 (zh) 2009-06-12 2013-01-17 用於治療過早衰老和尤其是早衰的化合物
HK16101080.1A HK1213247A1 (zh) 2009-06-12 2013-01-17 用於治療過早衰老和尤其是早衰的化合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK13100731.9A HK1173447A1 (zh) 2009-06-12 2013-01-17 用於治療過早衰老和尤其是早衰的化合物
HK16100761.9A HK1212702A1 (zh) 2009-06-12 2013-01-17 用於治療過早衰老和尤其是早衰的化合物
HK15101062.4A HK1200363A1 (zh) 2009-06-12 2015-01-30 用於治療癌症的化合物

Country Status (24)

Country Link
US (7) US20120277230A1 (zh)
EP (6) EP3517534B1 (zh)
JP (8) JP5826745B2 (zh)
KR (14) KR20120051643A (zh)
CN (13) CN102574835B (zh)
AU (3) AU2010258294B2 (zh)
BR (5) BRPI1012892B8 (zh)
CA (5) CA2965791C (zh)
CU (4) CU24461B1 (zh)
DK (4) DK2440546T3 (zh)
ES (3) ES2736198T3 (zh)
FI (3) FI2440547T3 (zh)
HK (8) HK1173153A1 (zh)
HR (2) HRP20230143T1 (zh)
HU (2) HUE045548T2 (zh)
LT (1) LT2440547T (zh)
MX (9) MX367601B (zh)
PL (3) PL2440547T3 (zh)
PT (3) PT2440547T (zh)
RU (1) RU2567752C2 (zh)
SI (1) SI2440547T1 (zh)
TR (1) TR201910781T4 (zh)
WO (3) WO2010143168A2 (zh)
ZA (2) ZA201109031B (zh)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2440546T3 (da) 2009-06-12 2023-03-27 Abivax Forbindelser, der er anvendelige til behandling af for tidlig aldring og især progeria
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
MX2019008390A (es) * 2009-06-12 2019-09-09 Abivax Compuestos utiles para tratar cancer.
BR112012004533B1 (pt) 2009-09-03 2021-11-09 Bioenergenix Composto, composição farmacêutica, e uso do composto
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2465502A1 (en) * 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
US9073902B2 (en) 2011-01-05 2015-07-07 Bioenergenix, Llc Substituted quinoxaline carboxylic acid compounds for the inhibition of PASK
JP6139415B2 (ja) 2011-03-02 2017-05-31 バイオエナジェニックス Ｐａｓｋの阻害のための複素環化合物
US8916561B2 (en) 2011-03-02 2014-12-23 Bioenergenix, Llc Substituted quinoxaline compounds for the inhibition of PASK
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
FR2987627B1 (fr) 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
WO2013192423A2 (en) * 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
WO2014022728A1 (en) 2012-08-02 2014-02-06 Endo Pharmaceuticals, Inc Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer
WO2014028479A1 (en) 2012-08-13 2014-02-20 Envoy Therapeutics, Inc. Quinoxaline derivatives as gpr6 modulators
WO2014065209A1 (ja) * 2012-10-23 2014-05-01 日本曹達株式会社 ピリジン化合物またはその塩、有害生物防除剤、殺虫剤または殺ダニ剤、および外部寄生虫防除剤
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
GB201301571D0 (en) * 2012-11-27 2013-03-13 Fundanci N Pedro Barri De La Maza Product and use
US20140194465A1 (en) * 2013-01-04 2014-07-10 Novarx Corporation Compositions for treatment of cancer
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
CN105530938B (zh) * 2013-07-05 2019-10-22 Abivax公司 用于治疗由逆转录病毒引起的疾病的化合物
JPWO2015005491A1 (ja) 2013-07-12 2017-03-02 国立大学法人京都大学 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
AU2014342269B2 (en) 2013-10-30 2020-02-27 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
JO3466B1 (ar) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
US10179783B2 (en) 2014-02-14 2019-01-15 Taketa Pharmaceutical Company Limited Tetrahydropyridopyrazines as modulators of GPR6
AU2015238301B2 (en) 2014-03-26 2020-06-25 Astex Therapeutics Ltd Combinations
KR102479696B1 (ko) 2014-03-26 2022-12-22 아스텍스 테라퓨틱스 리미티드 Fgfr 억제제 및 igf1r 억제제의 조합물
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
EP2975034A1 (en) 2014-07-17 2016-01-20 Abivax A quinoline derivative for the treatment of inflammatory diseases and AIDS
EP2974729A1 (en) * 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
JP6990586B2 (ja) 2015-01-30 2022-01-12 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック デルタ１３３ｐ５３ベータおよびデルタ１３３ｐ５３ガンマアイソフォームはがん幹細胞のバイオマーカーである
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
EP3059591A1 (en) * 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
EP3059236A1 (en) 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
EP3058940A1 (en) 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HUE050567T2 (hu) 2015-09-23 2020-12-28 Janssen Pharmaceutica Nv Triciklusos heterociklusok rák kezelésére
CA2996989C (en) 2015-09-23 2023-10-03 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
MX2018007361A (es) 2015-12-17 2019-05-16 Biokine Therapeutics Ltd Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas.
US10646465B2 (en) 2015-12-17 2020-05-12 Biokine Therapeutics Ltd. Small molecules against cancer
EA035621B1 (ru) * 2016-02-03 2020-07-16 Янссен Фармацевтика Нв Лиганды для pet-визуализации тау-белков
PT3429998T (pt) 2016-03-18 2021-11-04 Prosynergia S A R L Processo para preparação de derivados de quinolin-2-il-fenilamina e seus sais
ES2846833T3 (es) * 2016-07-18 2021-07-29 Janssen Pharmaceutica Nv Ligandos de obtención de imágenes de tau por PET
CN106496061B (zh) * 2016-10-20 2018-06-05 湘潭大学 一种萃取分离酰化反应液中乙酰精胺的方法
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
US10323289B2 (en) 2017-06-26 2019-06-18 Institut Pasteur Treatments to eliminate HIV reservoirs and reduce viral load
US10889566B2 (en) * 2017-08-29 2021-01-12 Chulabhorn Foundation Derivatives and composition of quinoline and naphthyridine
US20200039989A1 (en) * 2018-03-01 2020-02-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk/clk and uses thereof
WO2019186277A1 (en) 2018-03-28 2019-10-03 Institut Pasteur Ultrasensitive hiv-1 p24 detection assay
EP3594205A1 (en) * 2018-07-09 2020-01-15 Abivax Phenyl-n-aryl derivatives for treating a rna virus infection
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
EP3669874A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use in the treatment or prevention of cancer
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
KR20220009442A (ko) 2019-05-15 2022-01-24 아론바이오 리미티드 암 치료, 케모카인 활성 억제 및/또는 세포사 유도를 위한 소분자
CU20220041A7 (es) 2020-01-31 2023-03-07 Abivax Dispersión sólida amorfa de 8-cloro-n-(4-(trifluorometoxi)fenil)quinolin-2-amina
EP3858336A1 (en) 2020-01-31 2021-08-04 Abivax Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
EP3858815A1 (en) 2020-01-31 2021-08-04 Abivax Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
EP4121053A1 (en) 2020-03-20 2023-01-25 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
EP4175719A1 (en) 2020-07-02 2023-05-10 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
EP4063351A1 (en) 2021-03-26 2022-09-28 Abivax Preparation method of quinoline derivative compounds
KR20240014059A (ko) 2021-05-27 2024-01-31 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 퀴놀린아민 화합물, 이의 제조 방법 및 약제에서의 이의 용도
KR20230072900A (ko) 2021-11-18 2023-05-25 동우 화인켐 주식회사 마이크로 led 구조체 및 이의 제조방법
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
EP4215196A1 (en) 2022-01-24 2023-07-26 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor
TW202333698A (zh) * 2022-01-24 2023-09-01 大陸商江蘇恆瑞醫藥股份有限公司 喹啉胺類化合物、其製備方法及其在醫藥上的應用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR400973A (fr) 1909-03-19 1909-08-13 Jean Victor Massillon Nouveau sertisseur à main pour la fabrication des cartouches
GB585362A (en) 1944-08-31 1947-02-05 Francis Henry Swinden Curd New heterocyclic compounds
BE486034A (zh) 1947-11-28
DE958647C (de) 1952-12-28 1957-02-21 Hoechst Ag Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen
FR2387229A1 (fr) 1977-04-13 1978-11-10 Anvar Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
FR2436786A1 (fr) 1978-09-21 1980-04-18 Anvar Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments
FR2627493B1 (fr) 1988-02-23 1991-10-31 Sanofi Sa Procede de preparation de derives d'isoquinoleine
FR2645861A1 (fr) * 1989-04-17 1990-10-19 Inst Nat Sante Rech Med Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
WO2000059875A2 (en) 1999-04-05 2000-10-12 City Of Hope Novel inhibitors of formation of advanced glycation endproducts (age's)
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
DE10013318A1 (de) * 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
SK9152003A3 (en) 2001-01-22 2004-04-06 Memory Pharm Corp Aniline derivatives useful as phosphodiesterase 4 inhibitors
CA2486376A1 (en) 2002-05-22 2003-12-04 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
JP2006504656A (ja) * 2002-07-19 2006-02-09 メモリー・ファーマシューティカルズ・コーポレイション Ｎ−置換されたアニリン及びジフェニルアミンアナログを含むホスホジエステラーゼ４インヒビター
WO2006081444A2 (en) 2005-01-28 2006-08-03 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
FR2849474B3 (fr) 2002-12-27 2004-12-03 Olivier Jean Noel Juin Installation de transformation de l'energie cinetique d'un fluide en energie electrique
WO2004078731A1 (fr) 2003-03-06 2004-09-16 'chemical Diversity Research Institute', Ltd. Acides quinoline-carboxyliques et leurs derives et bibliotheque focalisee
WO2004080463A1 (en) 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
FR2859474B1 (fr) 2003-09-04 2006-01-13 Centre Nat Rech Scient Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
FR2859475A1 (fr) 2003-09-04 2005-03-11 Centre Nat Rech Scient Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
AU2004281154A1 (en) * 2003-10-16 2005-04-28 Novartis Vaccines And Diagnostics, Inc. 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer
PT1682138E (pt) * 2003-11-19 2011-02-28 Array Biopharma Inc Inibidores heterocíclicos de mek
WO2006051311A1 (en) 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
EP1897914A4 (en) 2005-06-29 2008-07-02 Adeka Corp RESIN ADDITIVE COMPOSITION AND RESIN COMPOSITION
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
US8030487B2 (en) * 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
CA2675358C (en) * 2007-01-19 2016-01-05 Ardea Biosciences, Inc. Inhibitors of mek
FR2912745A1 (fr) 2007-02-19 2008-08-22 Centre Nat Rech Scient Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
US20100249184A1 (en) * 2007-03-16 2010-09-30 Mount Sinai School Of Medicine Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction
TWI371445B (en) * 2007-05-17 2012-09-01 Lg Chemical Ltd New anthracene derivatives and organic electronic device using the same
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
JP2010536789A (ja) 2007-08-15 2010-12-02 メモリー・ファーマシューティカルズ・コーポレイション ５−ｈｔ６受容体親和性を有する３’置換化合物
WO2009029617A1 (en) * 2007-08-27 2009-03-05 Kalypsys, Inc. Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors
KR100974562B1 (ko) * 2007-12-31 2010-08-06 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고있는 유기 발광 소자
FR2926297B1 (fr) 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
WO2010076339A1 (en) * 2009-01-05 2010-07-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants
US20110275791A1 (en) * 2009-01-06 2011-11-10 Ziad Mallat A B Cell Depleting Agent for the Treatment of Atherosclerosis
CN102272090A (zh) * 2009-01-06 2011-12-07 帝斯曼知识产权资产管理有限公司 制备白藜芦醇中间体的方法
EP2266972A1 (en) 2009-06-12 2010-12-29 Splicos New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
DK2440546T3 (da) * 2009-06-12 2023-03-27 Abivax Forbindelser, der er anvendelige til behandling af for tidlig aldring og især progeria
MX2019008390A (es) 2009-06-12 2019-09-09 Abivax Compuestos utiles para tratar cancer.
US8962583B2 (en) 2009-06-25 2015-02-24 The Brigham And Women's Hospital, Inc. Treatment of inflammatory diseases using miR-124
EP2465502A1 (en) 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
WO2014055944A1 (en) 2012-10-04 2014-04-10 Oyagen, Inc. Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
JP2015120566A (ja) * 2013-12-20 2015-07-02 ニチユ三菱フォークリフト株式会社 荷役車両

Also Published As

Publication number Publication date
KR20170124646A (ko) 2017-11-10
BRPI1010772B8 (pt) 2021-05-25
PL2440545T3 (pl) 2019-11-29
MX2011013122A (es) 2012-07-23
KR20190018568A (ko) 2019-02-22
DK2440547T3 (da) 2023-02-20
AU2010258295A1 (en) 2012-01-19
CN106928194A (zh) 2017-07-07
JP6158250B2 (ja) 2017-07-05
KR101769616B1 (ko) 2017-08-18
DK3517534T3 (da) 2024-05-27
WO2010143168A3 (en) 2011-06-09
CU24461B1 (es) 2020-01-03
EP3517534B1 (en) 2024-02-28
CN104844570B (zh) 2018-11-02
KR102016889B1 (ko) 2019-08-30
KR20190018567A (ko) 2019-02-22
BRPI1010768B1 (pt) 2019-10-22
AU2010258214B2 (en) 2015-08-20
BRPI1010768A2 (pt) 2016-11-01
JP7042245B2 (ja) 2022-03-25
CA3070823A1 (en) 2010-12-16
CA2764026C (en) 2019-10-29
EP3521283B1 (en) 2024-02-28
EP2440545A2 (en) 2012-04-18
BRPI1010772B1 (pt) 2020-10-27
CU20150024A7 (es) 2015-09-29
EP2440546A2 (en) 2012-04-18
BRPI1010768A8 (pt) 2019-07-30
BRPI1010768B8 (pt) 2020-03-10
US20140288120A1 (en) 2014-09-25
EP2440547A2 (en) 2012-04-18
JP6158251B2 (ja) 2017-07-05
KR102016893B1 (ko) 2019-08-30
KR20180100736A (ko) 2018-09-11
PT2440547T (pt) 2023-02-17
ES2736198T3 (es) 2019-12-26
MX364282B (es) 2019-04-22
JP2015187151A (ja) 2015-10-29
CU20110228A7 (es) 2012-04-15
CU24124B1 (es) 2015-08-27
CN104945379B (zh) 2018-11-30
BRPI1010772A2 (pt) 2016-11-01
CN104844510B (zh) 2019-04-23
KR101982463B1 (ko) 2019-05-24
KR20170092720A (ko) 2017-08-11
WO2010143169A2 (en) 2010-12-16
WO2010143168A2 (en) 2010-12-16
CN106928194B (zh) 2019-11-12
FI2440547T3 (fi) 2023-03-14
CU20110230A7 (es) 2012-04-15
CN109776496B (zh) 2021-09-28
US10017498B2 (en) 2018-07-10
MX338823B (es) 2016-05-03
BR122019013686B1 (pt) 2020-03-17
CN102574835B (zh) 2014-04-16
AU2010258294B2 (en) 2015-07-30
BRPI1010768C8 (pt) 2020-04-07
PL2440546T3 (pl) 2023-07-10
CN106928205B (zh) 2019-09-24
CN106905232A (zh) 2017-06-30
CN104844510A (zh) 2015-08-19
AU2010258294A1 (en) 2012-01-19
KR20120051643A (ko) 2012-05-22
PT2440545T (pt) 2019-07-19
DK2440545T3 (da) 2019-07-22
JP2015155453A (ja) 2015-08-27
AU2010258295B2 (en) 2015-09-03
RU2011149571A (ru) 2013-07-20
EP3521283A1 (en) 2019-08-07
MX340095B (es) 2016-06-27
JP2012529494A (ja) 2012-11-22
JP2012529493A (ja) 2012-11-22
KR20190018570A (ko) 2019-02-22
KR20120049860A (ko) 2012-05-17
PT2440546T (pt) 2023-03-27
HRP20230248T1 (hr) 2023-04-14
HUE061262T2 (hu) 2023-05-28
CN104945378A (zh) 2015-09-30
EP3517534A1 (en) 2019-07-31
CN113004249A (zh) 2021-06-22
MX2011013119A (es) 2012-07-04
CN109776496A (zh) 2019-05-21
LT2440547T (lt) 2023-03-10
EP2440545B1 (en) 2019-04-24
KR101863021B1 (ko) 2018-05-30
HK1173153A1 (zh) 2013-05-10
CA2764024A1 (en) 2010-12-16
KR102016890B1 (ko) 2019-08-30
BRPI1012892B8 (pt) 2021-05-25
KR101982462B1 (ko) 2019-05-24
SI2440547T1 (sl) 2023-05-31
BR122019013687B1 (pt) 2020-04-14
FI3517534T3 (fi) 2024-05-16
KR101789275B1 (ko) 2017-11-20
DK2440546T3 (da) 2023-03-27
CN102625804A (zh) 2012-08-01
WO2010143169A3 (en) 2011-11-10
KR101982461B1 (ko) 2019-05-24
CN106905232B (zh) 2019-09-27
HK1213247A1 (zh) 2016-06-30
EP2440547B1 (en) 2022-11-30
HRP20230143T1 (hr) 2023-03-31
KR20190018571A (ko) 2019-02-22
US20150307478A1 (en) 2015-10-29
BRPI1012892A2 (pt) 2018-03-13
HK1173447A1 (zh) 2013-05-16
HK1200363A1 (zh) 2015-08-07
CA2965791A1 (en) 2010-12-16
KR101973348B1 (ko) 2019-04-26
MX364279B (es) 2019-04-22
CN104844570A (zh) 2015-08-19
MX364280B (es) 2019-04-22
US20140080831A1 (en) 2014-03-20
FI2440546T3 (fi) 2023-03-30
JP2020045342A (ja) 2020-03-26
CU24245B1 (es) 2017-02-02
JP2015187150A (ja) 2015-10-29
ZA201109032B (en) 2013-02-27
CU20110229A7 (es) 2012-06-21
HK1213246A1 (zh) 2016-06-30
KR102016891B1 (ko) 2019-08-30
CN104945379A (zh) 2015-09-30
CN106928205A (zh) 2017-07-07
CN103948594B (zh) 2016-10-26
ZA201109031B (en) 2013-02-27
HK1173726A1 (zh) 2013-05-24
US9108919B2 (en) 2015-08-18
MX2011013120A (es) 2012-07-23
HUE045548T2 (hu) 2019-12-30
CN102574835A (zh) 2012-07-11
US20120277230A1 (en) 2012-11-01
HK1212702A1 (zh) 2016-06-17
JP2015187152A (ja) 2015-10-29
BRPI1012892B1 (pt) 2020-10-27
CA2764027A1 (en) 2010-12-16
MX353776B (es) 2018-01-29
US9637475B2 (en) 2017-05-02
MX364989B (es) 2019-05-17
CN104945378B (zh) 2018-11-20
KR20180100737A (ko) 2018-09-11
EP2440546B1 (en) 2022-12-28
RU2011149572A (ru) 2013-07-20
CN102625804B (zh) 2015-04-08
RU2567752C2 (ru) 2015-11-10
KR102016892B1 (ko) 2019-08-30
KR20180101727A (ko) 2018-09-13
US20120283265A1 (en) 2012-11-08
JP5905385B2 (ja) 2016-04-20
AU2010258214A1 (en) 2012-01-19
CA2965791C (en) 2020-06-09
US20150299129A1 (en) 2015-10-22
JP5826745B2 (ja) 2015-12-02
EP4198022A1 (en) 2023-06-21
CN103948594A (zh) 2014-07-30
US20120329796A1 (en) 2012-12-27
MX359575B (es) 2018-10-03
JP2012529495A (ja) 2012-11-22
CU24093B1 (es) 2015-04-29
CA2764027C (en) 2020-11-03
US9908869B2 (en) 2018-03-06
KR20180100735A (ko) 2018-09-11
CA2764024C (en) 2017-12-05
WO2010143170A2 (en) 2010-12-16
MX367601B (es) 2019-08-28
PL2440547T3 (pl) 2023-09-11
JP6041671B2 (ja) 2016-12-14
KR20190018569A (ko) 2019-02-22
ES2940885T3 (es) 2023-05-12
CA2764026A1 (en) 2010-12-16
KR20120054585A (ko) 2012-05-30
KR101897221B1 (ko) 2018-09-10
TR201910781T4 (tr) 2019-08-21
CA3070823C (en) 2021-09-21
US9145367B2 (en) 2015-09-29
WO2010143170A3 (en) 2011-08-11
CN102596935A (zh) 2012-07-18
CN102596935B (zh) 2015-02-18
ES2938532T3 (es) 2023-04-12

Similar Documents

Publication Publication Date Title
HK1212702A1 (zh) 用於治療過早衰老和尤其是早衰的化合物
HRP20170936T1 (hr) Alkilamido spojevi i njihova uporaba
EP2259796A4 (en) MATERIALS AND METHODS FOR IMPROVED IMMUNE LYCOPROTEINS
EP2271218A4 (en) USE AND COMPOSITION FOR THE TREATMENT OF DEMENTIA
EP2413365A4 (en) MOSFET AND MOSFET MANUFACTURING METHOD
PL2396321T3 (pl) Kompozycje i sposoby zwalczania nicieni
EP2333376A4 (en) SELF ADJUSTER
IL210097A0 (en) Compositions and methods for treating unfluenza
HK1162058A1 (zh) 鞣製方法和鞣製組合物
EP2504428A4 (en) METHOD AND COMPOSITIONS FOR TREATING OXALATE-MEDIATED SUFFERING
GB0912468D0 (en) Composition and method
HK1169993A1 (zh) 可用於治療糖尿病的 抑制劑
EP2413364A4 (en) MOS TRANSISTOR AND METHOD FOR MANUFACTURING THE SAME
IL243809A0 (en) Process for the production of γ-ketosulfide compound and γ-ketosulfide compounds
ZA201007680B (en) Method of treating metalliferrous materials
ZA201101838B (en) Seal and process for its manufacturing
GB0901667D0 (en) Composition and method
GB0807102D0 (en) Process and composition
GB0807336D0 (en) Composition and process
GB0815743D0 (en) Novel processes and materials
GB0912714D0 (en) Composition and process
HU0800726D0 (en) Process and kit
GB0806334D0 (en) Method and composition
GB0816946D0 (en) Composition and method
GB0817553D0 (en) Composition and method